首页> 外文期刊>Journal of natural medicines >Taxonomic examination of longgu (Fossilia Ossis Mastodi, “dragon bone”) and a related crude drug, longchi (Dens Draconis, “dragon tooth”), from Japanese and Chinese crude drug markets
【24h】

Taxonomic examination of longgu (Fossilia Ossis Mastodi, “dragon bone”) and a related crude drug, longchi (Dens Draconis, “dragon tooth”), from Japanese and Chinese crude drug markets

机译:Longgu(骨质骨质雌蕊米斯蒂迪,“龙骨”)和相关的粗药,龙池(Dens Draconis,“龙齿”),来自日本和中国粗药物

获取原文
获取原文并翻译 | 示例
       

摘要

Abstract Longgu (“dragon bone,” Ryu - kotsu , Fossilia Ossis Mastodi, or Os Draconis) is the only fossil crude drug listed in the Japanese Pharmacopoeia. All longgu in the current Japanese market is imported from China, where its resources are being depleted. Therefore, effective countermeasures are urgently needed to prevent resource depletion. One possible solution is the development of a substitute made from bones of contemporary animals that are closely related to the original animal source of the current longgu. However, no research has been conducted on the original animal source of longgu, except for a report on the longgu specimens present in the Shosoin Repository. Taxonomic examination was performed on the fossil specimens related to longgu which are owned by the Museum of Osaka University, Japan. In total, 20,939 fossil fragments were examined, of which 20,886 were mammalian fossils, and 246 of these fossils were classified into nine families. The longgu specimens from the Japanese market belonged to a relatively smaller variety of taxa than those from the Chinese market. Despite the variety of taxa in longgu, medical doctors using Kampo preparations with longgu have not reported any problems due to the presence of impurities in the original animal source. These results suggest that the effect of longgu is independent of its origin as long as it is closely related to the origin of the current longgu. Thus, despite the considerable effects of fossilization, our results could help in developing an optimal substitute for longgu. ]]>
机译:摘要LongGu(“Dragon Bone,”Ryu - Kotsu,Fossilia Ossis Mastodi或Os Draconis)是日本药典中唯一列入的化石粗药。目前日本市场的所有Longgu都从中国进口,资源正在耗尽。因此,迫切需要有效的对策来防止资源耗尽。一种可能的解决方案是开发由与当前动物的当代动物的骨骼进行的替代品的开发,与当前LongGU的原始动物来源密切相关。然而,除了在Shosooin储存库中存在的LongGu样本的报告之外,LongGu的原始动物来源没有研究。对与日本大阪大学博物馆拥有的LongGu相关的化石标本进行分类学检查。总共检查了20,939个化石片段,其中20,886个是哺乳动物化石,这些化石中的246个分为九个家庭。来自日本市场的LongGu标本属于相对较小的分类群,而不是中国市场的分类群。尽管Longgu的各种分类群,但使用Kampo制剂与Longgu的医生尚未报告原有的动物来源中杂质的存在。这些结果表明,只要它与当前LongGu的起源密切相关,LongGu的效果就与其起源无关。因此,尽管僵化效果相当大,但我们的结果可以帮助开发LongGu的最佳替代品。 ]]>

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号